Crizotinib

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 3896 publications

US population-level model of clinical impact of lorlatinib treatment on ALK+ metastatic non-small cell lung cancer outcomes.

US population-level model of clinical impact of lorlatinib treatment on ALK+ metastatic non-small cell lung cancer outcomes.

Journal: Journal of comparative effectiveness research
Published: September 03, 2026

Clinical characteristics of ALK-positive NSCLC patients treated with sequential ALK-TKI therapies in a single-centre.

Clinical characteristics of ALK-positive NSCLC patients treated with sequential ALK-TKI therapies in a single-centre.

Journal: Lung cancer management
Published: July 27, 2026

Expert consensus on iruplinalkib for the treatment of ALK-positive non-small cell lung cancer (2026 edition)

Expert consensus on iruplinalkib for the treatment of ALK-positive non-small cell lung cancer (2026 edition)

Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology]
Published: July 25, 2026

Cost of managing brain metastases in patients with ALK+ advanced NSCLC with first-line tyrosine kinase inhibitors in the UK.

Cost of managing brain metastases in patients with ALK+ advanced NSCLC with first-line tyrosine kinase inhibitors in the UK.

Journal: Lung cancer management
Published: July 21, 2026

Endobronchial mass in an adult: an unusual presentation of inflammatory myofibroblastic tumour.

Endobronchial mass in an adult: an unusual presentation of inflammatory myofibroblastic tumour.

Journal: BMJ case reports
Published: July 21, 2026

In the era of adjuvant alectinib, what can we learn from the E4512 trial of adjuvant crizotinib?

In the era of adjuvant alectinib, what can we learn from the E4512 trial of adjuvant crizotinib?

Journal: The Lancet. Respiratory medicine
Published: July 13, 2026

Allosteric kinase inhibition in hematological malignancies: from asciminib to emerging regulatory sites.

Allosteric kinase inhibition in hematological malignancies: from asciminib to emerging regulatory sites.

Journal: Biochemical pharmacology
Published: July 10, 2026

Longitudinal Treatment Outcomes in Patients With Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer: Results From a Multinational Registry-Based Study in a Predominantly Western Population.

Longitudinal Treatment Outcomes in Patients With Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer: Results From a Multinational Registry-Based Study in a Predominantly Western Population.

Journal: JCO global oncology
Published: June 24, 2026

Response to Crizotinib in Infantile Fibrosarcoma with TFG::MET Gene Fusion.

Response to Crizotinib in Infantile Fibrosarcoma with TFG::MET Gene Fusion.

Journal: The New England journal of medicine
Published: June 24, 2026

Treatment of ALK+ Non-Small Cell Lung Cancer in the Brazilian Public and Private Health Care Systems: A Tale of Inequalities (LACOG/GBOT 1918).

Treatment of ALK+ Non-Small Cell Lung Cancer in the Brazilian Public and Private Health Care Systems: A Tale of Inequalities (LACOG/GBOT 1918).

Journal: JCO global oncology
Published: June 24, 2026

Fusion isoform multiplicity and impact on treatment outcomes in ALK-rearranged non-small cell lung cancer with next-generation tyrosine kinase inhibitors.

Fusion isoform multiplicity and impact on treatment outcomes in ALK-rearranged non-small cell lung cancer with next-generation tyrosine kinase inhibitors.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: June 11, 2026

Substituent Effects of Heptamethine Cyanine Dyes on Drug Uptake in Patient-Derived Glioma Cells.

Substituent Effects of Heptamethine Cyanine Dyes on Drug Uptake in Patient-Derived Glioma Cells.

Journal: ChemMedChem
Published: June 08, 2026
Showing 1-12 of 3,896

Last Updated: 09/26/2026